KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation & Amortization - Total (2016 - 2021)

Arbutus Biopharma (ABUS) has disclosed Depreciation & Amortization - Total for 9 consecutive years, with $447000.0 as the latest value for Q3 2021.

  • Quarterly Depreciation & Amortization - Total fell 8.78% to $447000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $447000.0 through Jun 2022, down 75.92% year-over-year, with the annual reading at $2.0 million for FY2020, 2.47% down from the prior year.
  • Depreciation & Amortization - Total hit $447000.0 in Q3 2021 for Arbutus Biopharma, up from $436000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $620000.0 in Q4 2017 to a low of $334000.0 in Q1 2017.
  • Historically, Depreciation & Amortization - Total has averaged $502105.3 across 5 years, with a median of $501000.0 in 2020.
  • Biggest five-year swings in Depreciation & Amortization - Total: skyrocketed 103.78% in 2017 and later dropped 18.71% in 2018.
  • Year by year, Depreciation & Amortization - Total stood at $620000.0 in 2017, then dropped by 18.71% to $504000.0 in 2018, then rose by 0.6% to $507000.0 in 2019, then fell by 3.94% to $487000.0 in 2020, then dropped by 8.21% to $447000.0 in 2021.
  • Business Quant data shows Depreciation & Amortization - Total for ABUS at $447000.0 in Q3 2021, $436000.0 in Q2 2021, and $443000.0 in Q1 2021.